WO2022101412A1 - A magl inhibitor - Google Patents

A magl inhibitor Download PDF

Info

Publication number
WO2022101412A1
WO2022101412A1 PCT/EP2021/081522 EP2021081522W WO2022101412A1 WO 2022101412 A1 WO2022101412 A1 WO 2022101412A1 EP 2021081522 W EP2021081522 W EP 2021081522W WO 2022101412 A1 WO2022101412 A1 WO 2022101412A1
Authority
WO
WIPO (PCT)
Prior art keywords
azaspiro
octane
hexafluoropropan
carboxylate
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/081522
Other languages
English (en)
French (fr)
Inventor
John J. M. Wiener
Cheryl A. Grice
Daniel J. Buzard
Justin S. CISAR
Olivia D. WEBER
Amy Allan
Nicholas Raffaele
Jeanne V. Moody
Michael B. SHAGHAFI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FIEP21811018.7T priority Critical patent/FI4244208T3/fi
Priority to CN202512011225.8A priority patent/CN121824488A/zh
Priority to SI202130311T priority patent/SI4244208T1/sl
Priority to IL301818A priority patent/IL301818B1/en
Priority to US18/252,611 priority patent/US20240018120A1/en
Priority to PL21811018.7T priority patent/PL4244208T3/pl
Priority to CN202180073621.0A priority patent/CN116547274B/zh
Priority to JP2023524567A priority patent/JP2023549051A/ja
Priority to MX2023005576A priority patent/MX2023005576A/es
Priority to RS20250496A priority patent/RS66839B1/sr
Priority to HRP20250644TT priority patent/HRP20250644T1/hr
Priority to CR20230203A priority patent/CR20230203A/es
Priority to UAA202301351A priority patent/UA130186C2/uk
Priority to EP25166976.8A priority patent/EP4574150A3/en
Priority to KR1020237015365A priority patent/KR20230107225A/ko
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to EP21811018.7A priority patent/EP4244208B1/en
Priority to LTEPPCT/EP2021/081522T priority patent/LT4244208T/lt
Priority to MA62148A priority patent/MA62148B1/fr
Priority to AU2021379081A priority patent/AU2021379081A1/en
Priority to CA3196119A priority patent/CA3196119A1/en
Priority to ES21811018T priority patent/ES3025484T3/es
Priority to DK21811018.7T priority patent/DK4244208T3/da
Publication of WO2022101412A1 publication Critical patent/WO2022101412A1/en
Priority to ZA2023/04134A priority patent/ZA202304134B/en
Priority to CONC2023/0004649A priority patent/CO2023004649A2/es
Priority to SA523440403A priority patent/SA523440403B1/ar
Priority to JOJO/P/2023/0091A priority patent/JOP20230091A1/ar
Priority to DO2023000086A priority patent/DOP2023000086A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

  • the present invention relates to compounds which are monoacylglycerol lipase (MAGL) inhibitors.
  • MAGL monoacylglycerol lipase
  • MAGL is a member of the serine hydrolase superfamily. MAGL is expressed throughout the brain, in neurons, microglia, astrocytes, and oligodendrocytes. MAGL is the primary enzyme controlling the degradation of 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) (Blankman et al. Chem Biol. 2007; Nomura et al. Science. 2011).
  • 2-AG 2-arachidonoylglycerol
  • AA arachidonic acid
  • 2-AG is the most abundant endocannabinoid ligand in the brain, where it acts as a retrograde messenger to reduce excessive neurotransmission via the activation of pre-synaptic CBi receptors (Kano et al. Physiol Rev. 2009; Katona and Freund. Physiol Rev. 2009), regulating immune response via the activation of microglial CB? receptors (Turcotte et al. Cell Mol Life Sci. 2016), and promotes neuroprotection via e.g., its effects on oligodendrocyte production and survival (Ilyasov et al. Front Neurosci. 2018).
  • AA is one of the most abundant fatty acids in the brain and the main precursor of eicosanoids such as prostanoids and leukotrienes, which are known inflammatory mediators.
  • MAGL is at the crossroads between the endocannabinoid and eicosanoid signalling systems. Inhibiting the action or activation of MAGL is a promising therapeutic approach for the prevention or treatment of brain disorders which pathological hallmarks include excessive neurotransmission, neuroinflammation or neurodegeneration such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), traumatic brain injury, stroke, epilepsy, pain, migraine, addiction, anxiety, depression and other stress-related disorders (Grabner et al. Pharmacol Ther. 2017; Mulvihill et al. Life Sci. 2013; Gil-Ordonez et al. Biochem Pharmacol. 2018).
  • WO2019/046318 discloses spirocyclic compounds, which are MAGL inhibitors.
  • W02019/046330 discloses spirocyclic compounds, which are MAGL inhibitors.
  • An objective of the present invention is to provide compounds that inhibit MAGL. Accordingly, the present invention provides a compound of Formula (I): wherein
  • R1 represents -C(0)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(0)NHC(0)R2;
  • R2 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle having one or two heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R3 and R4 together with the N to which they are attached form a 9 or 10 membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6 membered heterocycle having one or two heteroatoms independently selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C3-C7 cycloalkyl, 7 membered bicyclic heterocycle, or 9 or 10 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, - C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -P
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or a disorder selected from pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
  • a method for treating a neurological and/or psychiatric disorder selected from pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia, comprising a step of administering to a patient in need thereof a therapeutically effective amount a compound of Formula (I), or pharmaceutically acceptable salt thereof.
  • a disease or disorder selected from pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
  • FIG 1 Anti-nociceptive effects of Example 6 in the rat formalin model; y-axis: count - hind limb licking frequency; x-axis: time period(min). Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001.
  • FIG 2 Anti-nociceptive effects of Example 8 in the rat formalin model; y-axis: count - hind limb licking frequency; x-axis: time period(min). Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001.
  • FIG 3 Effect of Example 6 in the MEST model; y-axis: Estimated seizure threshold (CCso) current(mA); Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: ***p ⁇ 0.001.
  • FIG 4 Effect of Example 8 in the MEST model; y-axis: Estimated seizure threshold (CCso) current(mA); Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: ***p ⁇ 0.001.
  • FIG 5 Effect of Example 6 in the Kainic Acid Seizure Model; y-axis; count - number of animals from groups of 12 showing forelimb clonus. Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: ** ⁇ 0.01, *** ⁇ 0.001.
  • FIG 6 Effect of Example 8 in the Kainic Acid Seizure Model; y-axis; count - number of animals from groups of 12 showing forelimb clonus. Significance level for post-hoc comparisons (relative to the vehicle group) are indicated: *** ⁇ 0.001.
  • acceptable or “pharmaceutically acceptable”, with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated or does not abrogate the biological activity or properties of the compound, and is relatively nontoxic.
  • amelioration of the symptoms of a particular disease, disorder or condition by administration of a particular compound or pharmaceutical composition refers to any lessening of severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the compound or composition.
  • anti-nociceptive effect pertains to the ability of a compound to increase the tolerance to, treat, delay, and/or reduce pain in a subject.
  • co-administration or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
  • an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic uses is the amount of the composition including a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms without undue adverse side effects.
  • An appropriate “effective amount” in any individual case may be determined using techniques, such as a dose escalation study.
  • the term "therapeutically effective amount” includes, for example, a prophy lactically effective amount.
  • an “effective amount” of a compound disclosed herein is an amount effective to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects. It is understood that “an effective amount” or “a therapeutically effective amount” can vary from subject to subject, due to variation in metabolism of Compound (I), age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. By way of example only, therapeutically effective amounts may be determined by routine experimentation, including but not limited to a dose escalation clinical trial.
  • inhibitors refer to inhibition of enzymatic activity.
  • isolated refers to separating and removing a component of interest from components not of interest. Isolated substances can be in either a dry or semi-dry state, or in solution, including but not limited to an aqueous solution.
  • the isolated component can be in a homogeneous state or the isolated component can be a part of a pharmaceutical composition that comprises additional pharmaceutically acceptable carriers and/or excipients.
  • module means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
  • a modulator refers to a compound that alters an activity of a molecule.
  • a modulator can cause an increase or decrease in the magnitude of a certain activity of a molecule compared to the magnitude of the activity in the absence of the modulator.
  • a modulator is an inhibitor, which decreases the magnitude of one or more activities of a molecule.
  • an inhibitor completely prevents one or more activities of a molecule.
  • a modulator is an activator, which increases the magnitude of at least one activity of a molecule.
  • the presence of a modulator results in an activity that does not occur in the absence of the modulator.
  • p rophy lactica I ly effective amount refers that amount of a composition applied to a patient which will relieve to some extent one or more of the symptoms of a disease, condition or disorder being treated. In such prophylactic applications, such amounts may depend on the patient's state of health, weight, and the like. It is considered well within the skill of the art for one to determine such prophylactically effective amounts by routine experimentation, including, but not limited to, a dose escalation clinical trial.
  • subject refers to an animal which is the object of treatment, observation or experiment.
  • a subject may be, but is not limited to, a mammal including, but not limited to, a human.
  • target activity refers to a biological activity capable of being modulated by a selective modulator.
  • Certain exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzymatic activity, tumor growth, inflammation or inflammation- related processes, and amelioration of one or more symptoms associated with a disease or condition.
  • treat include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition.
  • the terms “treat,” “treating” or “treatment”, include, but are not limited to, prophylactic and/or therapeutic treatments.
  • the ICso refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response, such as inhibition of MAGL, in an assay that measures such response.
  • ECso refers to a dosage, concentration or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.
  • alkyl refer to a linear (i.e. unbranched) or branched saturated hydrocarbon having from one up to eight carbon atoms.
  • C1-C3 alkyl means a straight or branched chain hydrocarbon containing from 1 to 3 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2- methyl-l-butyl, n-hexyl, n-heptyl and n-octyl.
  • alkylene refers to a divalent group derived from a straight or branched chain hydrocarbon of 1 to 10 carbon atoms.
  • Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH2CH2-, - CH2CH(CH3)CH2CH2-, -CH(CH3)- and -CH2CH2CH2CH2CH2-.
  • alkoxy refers to a moiety of the formula -OR', wherein R' indicates alkyl as defined above.
  • C1-C3 alkoxy refers to such a moiety wherein the alkyl part has 1, 2, or 3 carbon atoms.
  • Examples of “C1-C3 alkoxy” include methoxy, ethoxy, n-propoxy, and isopropoxy.
  • cycloalkyl refers to a saturated ring system containing all carbon atoms as ring members and zero double bonds.
  • a cycloalkyl may be a monocyclic cycloalkyl (e.g., cyclopropyl) and preferably have between 3 to 7 carbon atoms in the ring.
  • halogen is intended to indicate a substituent selected from the 7th main group of the periodic table, such as fluoro, chloro or bromo.
  • fluoroalkyl is intended to refer to an alkyl group as defined hereinabove, with 1, 2, or 3 hydrogens replaced by fluoro.
  • An example of such group is trifluoromethyl.
  • hydroxyl or "hydroxy”, as used herein, means an -OH group.
  • hydroxyalkyl means at least one -OH group is appended to the parent molecular moiety through an alkylene group, as defined herein.
  • hydroxyhaloalkyl means at least one -OH group is appended to the parent molecular moiety through a haloalkyl group, as defined herein.
  • hydroxyfluoroalkyl means at least one -OH group is appended to the parent molecular moiety through a fluoroalkyl group, as defined herein.
  • oxo refers to an oxygen atom connected to another atom by a double bond. When the atom to which the oxygen is connected to carbon, the formed carbonyl group is indicated as -(CO)-.
  • 5 membered heteroaryl refers to a 5 membered aromatic ring wherein 1, 2 or 3 ring atoms are selected from O, N or S.
  • Examples of 5 membered heteroaryls of the present invention include thiophenyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl oxadiazolyl, and thiadiazolyl.
  • 6 membered heteroaryl refers to a 6 membered aromatic ring wherein 1, 2 or 3 ring atoms are selected independently from O, N, or S.
  • 6 membered heteroaryls of the present inventions include but are not limited to pyridyl, pyridazinyl, pyrimidinyl, pyranyl, diazinyl, and triazinyl.
  • a heterocyclic ring is intended to mean a 6 membered cyclic ring structure with 1 or 2 heteroatom(s) independently selected from N or O.
  • Examples of a 6 membered heterocycle include but are not limited to tetrahydropyranyl, piperidinyl, and morpholinyl,
  • bicyclic heterocycle refers to a mono heterocyclic ring appended to the parent moiety and forming a fused, spiro or a bridged ring system to a cycloalkyl group, monocyclic heterocycle, benzene ring, or a monocyclic 5 or 6 membered heteroaryl.
  • 7 membered bicyclic heterocycle means a bicycyclic heterocycle as defined above having 7 ringatoms and contains at least 1 heteroatom selected from N, O or S. Examples of a 7 membered bicyclic heterocycle include but are not limited 2-oxaspiro[3.3]heptan-6-yl.
  • 9 or 10 membered bicyclic heterocycle means a bicycyclic heterocycle as defined above having 9 or 10 ringatoms and contains at least 1 heteroatom selected from N, O or S.
  • Examples of a 9 or 10 membered bicyclic heterocycle include but are not limited 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl, 5, 6, 7, 8-tetrahydropyrido[4, 3-d] pyrimidinyl, 2-cyclopropyl-5,6,7,8-tetrahydropyrido[4, 3-d] pyrimidinyl, 3-cyclopropyl-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[l,2- a]pyrazinyl, or 5,6,
  • the present invention relates to a compound of Formula (I): wherein:
  • R1 represents -C(O)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(O)NHC(O)R2;
  • R2 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle having one or two heteroatoms independently selected from N or O, a C 3 -C? cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R3 and R4 together with the N to which they are attached form a 9 or 10 membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6 membered heterocycle having one or two heteroatoms independently selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C 3 -C?
  • cycloalkyl, 7 membered bicyclic heterocycle, or 9 or 10 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, Ci-C 3 alkyl, Ci-C 3 haloalky I, C 3 -Cs cycloalkyl, Ci-C 3 alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , - C(O)NHCH 3 , a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2 COOH; or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is a compound of Formula (la): wherein:
  • R1 represents -C(O)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(O)NHC(O)R2;
  • R2 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle having one or two heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R3 and R4 together with the N to which they are attached form a 9 or 10 membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6 membered heterocycle having one or two heteroatoms independently selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C3-C7 cycloalkyl, 7 membered bicyclic heterocycle, or 9 or 10 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -CfOjNH?, - C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -
  • the compound of the invention is a compound of Formula (lb):
  • R1 represents -C(O)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(O)NHC(O)R2;
  • R2 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle having one or two heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R3 and R4 together with the N to which they are attached form a 9 or 10 membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6 membered heterocycle having one or two heteroatoms independently selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C3-C7 cycloalkyl, 7 membered bicyclic heterocycle, or 9 or 10 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, - C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -P
  • R1 represents -C(O)NHR2
  • R2 represents a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S or a 6 membered heterocycle having one or two heteroatoms independently selected from N or O
  • each 5 or 6 membered heteroaryl or 6 membered heterocycle are independently unsubstituted or substituted with 1 substituent selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, -C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -P(O)(CH 3)2, and
  • R2 represents a 5 or 6 membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said 5 or 6 membered heteroaryl is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, - C(O)NH2, -C(O)NHCH3, a 5 membered heteroaryl having 1 or 2 heteroatoms selected independently from N or O, -NHSO2CH3, -P(O)(CH 3 )2, and -
  • R2 represents a 6 membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein said R2 is unsubstituted or substituted with 1 substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
  • R2 represents a 6 membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein said R2 is unsubstituted.
  • R2 is selected from the group consisting of:
  • R2 is selected from the group consisting of: wherein * denotes the point of attachment.
  • the compound of the invention is a compound of Formula (Ic), or a pharmaceutically acceptable salt thereof: wherein:
  • R5 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle, a C3-C7 cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R6 represents a hydrogen or methyl
  • W is -CH 2 - or -C(O)-; n is 0 or 1; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C3-C7 cycloalkyl, 7 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, -C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -PfOjfCHsh, and - OCH2COOH; or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is a compound of Formula (Id), or a pharmaceutically acceptable salt therof: wherein:
  • R5 represents a phenyl, a 5 or 6 membered heteroaryl having one or two heteroatoms independently selected from N, O and S, a 6 membered heterocycle, a C3-C7 cycloalkyl, or a 7 membered bicyclic heterocycle having one or two heteroatoms independently selected from N or O;
  • R6 represents a hydrogen or methyl
  • W is -CH2- or -C(O)-; n is 0 or 1; and wherein each phenyl, 5 or 6 membered heteroaryl, 6 membered heterocycle, C3-C7 cycloalkyl, 7 membered bicyclic heterocycle are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalky I, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, -C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, -NHSO2CH3, -PfOjfCHsh, and - OCH2COOH; or a pharmaceutically acceptable salt thereof.
  • R5 represents a 5 or 6 membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said R5 is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, Ci- C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, cyano, -NHC(O)CH3, -C(O)NH2, -C(O)NHCH3, a 5 membered heteroaryl having one or two heteroatoms independently selected from N or O, - NHSO2CH3, -P(O)(CH 3 )2, and -OCH2COOH.
  • R5 represents a 5 or 6 membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl
  • R5 represents a 6 membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, and pyrimidyl, wherein said 6 membered heteroaryl is unsubstituted.
  • R5 represents a 6 membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein said R5 is unsubstituted or substituted with 1 substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
  • R5 is selected from the group consisting of:
  • R5 is selected from the group consisting of: wherein * denotes the point of attachment.
  • R5 represents a 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl 2- oxaspiro[3.3]heptan-6-yl.
  • the compound of the invention is a compound of Formula (le), or a pharmaceutically acceptable salt therof: wherein R7 represents a phenyl, a 5 or 6 membered heteroaryl having one or two N atoms, or a 5 or 6 membered heterocycle having one heteroatom atom selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, or 5 or 6 membered heterocycle is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano.
  • the compound of the invention is a compound of Formula (If), or a pharmaceutically acceptable salt therof: wherein R7 represents a phenyl, a 5 or 6 membered heteroaryl having one or two N atoms, or a 5 or 6 membered heterocycle having one heteroatom selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, or 5 or 6 membered heterocycle is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano.
  • R7 represents a phenyl, a 5 or 6 membered heteroaryl having one or two N atoms, or a 5 or 6 membered heterocycle having one heteroatom selected from N or O; and wherein each phenyl, 5 or 6 membered heteroaryl, or 5 or 6 membered heterocycle
  • R7 represents pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said R7 is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano.
  • R7 represents tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein said R7 is unsubstituted or substituted with 1 substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
  • the compound of the invention is selected from the group consisting of: l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-( ⁇ )l-(tetrahydr
  • the compound of the invention is selected from the group consisting of: l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-(3-cyclopropyl-5,6,7,8-tetrahydro-
  • the compound of the invention is selected from the group consisting of: l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridazin-3-ylcarbamoyl)-6-
  • the compound of the invention is selected from the group consisting of: l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-
  • the compound of the invention is selected from the group consisting of: l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate; l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridin-4-
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- ((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- ((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • the compound of the invention is l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l- (pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • a pharmaceutical composition comprising a compound of Formula (I), (la), (lb), (Id), (le), or (If), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
  • a disease or disorder selected from the group consisting of: pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, spacsticity, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
  • the pain is neuropathic pain.
  • the pain is inflammatory pain.
  • the pain is selected from the group consisting of: acute pain, cancer pain, chronic pain, pain caused by peripheral neuropathy, central pain, pain caused by spinal cord injury, pain caused by stroke, complex regional pain syndrome, fibromyalgia, migraine, vasoocclussive painful crises in sickle cell disease, pain associated with multiple sclerosis, lower back pain, abdominal pain associated with irritable bowel syndrome functional chest pain, rheumatoid arthritis, osteoarthritis, somatoform disorders, or functional dyspepsia.
  • a disease or disorder selected from the group consisting of: pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, spacsticity, multiple sclerosis, obsessive- compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
  • a method for the treatment of a disease or disorder selected from the group consisting of: pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, spacsticity, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia comprising the administration of a therapeutically effective amount of a compound of Formula (I), (la), (lb), (Id), (le), or (If), or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • salts may be prepared in a conventional manner by treating a solution or suspension of a free base of formula (I) with a molar equivalent of a pharmaceutically acceptable acid.
  • suitable organic and inorganic acids are described below.
  • Pharmaceutically acceptable salts in the present context is intended to indicate non-toxic, i.e. physiologically acceptable salts.
  • salts formed with inorganic and/or organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid and benzene-sulfonic acid.
  • inorganic and/or organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, o
  • the compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers (i.e. enantiomers or diastereomers) as separated, enantiopure or partially purified optical isomers and any mixtures thereof including racemic mixtures, i.e. a mixture of stereoisomers, are included within the scope of the invention.
  • one embodiment of the invention relates to a compound of the invention having an enantiomeric excess (ee) of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
  • Racemic forms can be resolved into the optical antipodes by known methods, for example by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).
  • Optically active compounds can also be prepared from optically active starting materials or by the use of chiral catalysis.
  • Absolutestereochemistry may be determined by methods known to the skilled person, such as by Vibrational Circular Dichroism (VCD) Spectroscopy analysis.
  • VCD Vibrational Circular Dichroism
  • geometric isomers may be formed. It is intended that any geometric isomers as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
  • isotopica lly labelled compounds which are similar to those claimed in Formula (I), (la), (lb), (Ic), (Id), (le), or (If), or a pharmaceutically acceptable salt thereof, wherein one or more atoms are represented by an atom of the same element having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (e.g., 2 H, 3 H, n C, 13 C, 15 N, 18 F and the like). Particular mention is made of 2 H substituted compounds i.e. compounds wherein one or more H atoms are represented by deuterium.
  • one or more of the hydrogen atoms of the compound of Formula (I), (la), (lb), (Ic), (Id), (le), or (If), or a pharmaceutically acceptable salt thereof, are represented by deuterium. It is recognized that elements are present in natural isotopic abundances in most synthetic compounds, and result in inherent incorporation of deuterium. However, the natural isotopic abundance of hydrogen isotopes such as deuterium is immaterial (about 0.015%) relative to the degree of stable isotopic substitution of compounds indicated herein. Thus, as used herein, designation of an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium. Any atom not designated as a particular isotope is intended to represent any stable isotope of that atom, as will be apparent to the ordinarily skilled artisan.
  • the above-mentioned compounds or pharmaceutically acceptable salts may be in a composition as the sole active ingredient or in combination with other active ingredients. Additionally, one or more pharmaceutically acceptable carriers or diluents may be in the composition.
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
  • Suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, implants, etc.
  • the compounds of Formula (I), (la), (lb), (Ic), (Id), (le), or (If) are administered in a unit dosage form containing said compounds in an amount of about 0.1 to 500 mg, such as 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg 100 mg, 150 mg, 200 mg or 250 mg of a compound of the present invention.
  • solutions of the compounds of Formula (I), (la), (lb), (Ic), (Id), (le), or (If) in sterile aqueous solution aqueous propylene glycol may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phosphor lipids, polyoxyethylene and water.
  • compositions formed by combining the compounds of Formula (I), (la), (lb), (Ic), (Id), (le), or (If), or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
  • the preparation may be tablet, e.g. placed in a hard gelatine capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents followed by compression of the mixture in a conventional tabletting machine.
  • adjuvants or diluents comprise corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • the compounds of the present invention are intended for treatment of diseases and disorders which are linked to regulation of endocannabinoid system signaling activities where a MAGL inhibitor may be therapeutically beneficial.
  • a MAGL inhibitor may be therapeutically beneficial.
  • the compounds of the invention may be beneficial in indications which pathological hallmarks include excessive neurotransmission, neuroinflammation or neurodegeneration.
  • a disorder or disease selected from the group consisting of pain, epilepsy/seizure disorder, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive- compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
  • An exocannabinoid preparation is an approved treatment for spasticity associated with MS.
  • Sativex an oromucosal spray mixture of the CBi agonist THC and another cannabis plant derived alcohol, cannabidiol, was shown to decrease self-reported spasticity related symptoms.
  • Sativex an oromucosal spray mixture of the CBi agonist THC and another cannabis plant derived alcohol, cannabidiol
  • Other clinical trials have shown activity of a variety of exocannabinoids in spasticity due to MS (Zajicek et al., Lancet. 2003 ; Collin et al., Eur J Neurol. 2007; Collin et al., Neurol Res. 2010).
  • These parallel group studies exemplify the clinical trial design and endpoints that could be used to show a MAGL inhibitor benefits spasticity in MS.
  • a MAGL inhibitor will also be beneficial in the treatment of indications related to autoimmune encephalomyelitis.
  • a compound of Formula (I), (la), (lb), (Ic), (Id), (le), or (If), or pharmaceutically acceptable salt thereof for use in the treatment of Rasmussen encephalitis, Systemic lupus erythematosus, Behcet's disease, Hashimoto's encephalopathy, and Sydenham's chorea.
  • Central pain is neuropathic pain caused by lesion or dysfunction of the central nervous system, for example, post-stroke, multiple sclerosis, neuromyelitis optica, idiopathic inflammatory transverse myelitis, spinal cord injury, brachial-radial pain syndrome, and central craniofacial pain.
  • Exocannabinoids have demonstrated activity in central pain associated with multiple sclerosis.
  • a 4- week randomized double-blind placebo-controlled parallel group trial with MS and central pain using an oromucosal spray, THC/CBD, containing the CBi agonist delta-9-tetrahydrocannabinol and cannabidiol (another Cannabis-derived alcohol) showed that the active agent was superior to placebo in reducing the mean intensity of pain (N RS-11) and of sleep disturbance (Rog et al., Neurology. 2005).
  • THC/CBD The same THC/CBD preparation was studied in a larger group of MS patients with central neuropathic pain utilizing a two-stage design; in the second phase of this study, the time to treatment failure (primary endpoint) statistically favored THC/CBD, as did an improvement in the Pain NRS-11 and sleep quality (Langford et al., J Neurol. 2013). Additionally, nabilone, a synthetic CBi agonist structurally related to THC, showed efficacy in MS-induced central neuropathic pain (Turcotte et al., Pain Med. 2015). Studies of exocannabinoids in central pain have indicated activity, suggesting MAGL inhibitors may also have efficacy in treatment of central pain. Hence, in an embodiment is provided a compound of Formula (I), (la), (lb), (Ic), (Id), (le), or (If), or pharmaceutically acceptable salt thereof, for use in the treatment of central pain.
  • Fibromyalgia is a common, chronic, idiopathic condition characterized by diffuse body pain and the presence of pressure allodynia.
  • Duloxetine and pregabalin are specifically labeled for the treatment of pain in FM, and tricyclic antidepressants like amitriptyline, while not specifically labeled for FM treatment, are first-line agents.
  • tricyclic antidepressants like amitriptyline, while not specifically labeled for FM treatment
  • Migraine is a common episodic disorder of head and facial pain. Migraine attacks can be acutely treated with NSAIDs, acetaminophen, a variety of triptans (e.g., sumatriptan), and antiemetics, but some migraine sufferers have pain unresponsive to existing treatment options. Data suggest that endocannabinoid pathways may be relevant in migraine. In patients with chronic migraine and probable analgesic-overuse headache, CSF samples showed higher levels of the endocannabinoid palmitoylethanolamide and lower levels of anandamide compared with healthy controls (Sarchielli et al., Neuropsychopharmacology. 2007).
  • a retrospective chart review of patients attending a medical marijuana clinic with a primary diagnosis of migraine headaches found a decrease in the frequency of migraine headaches after initiating marijuana therapy (Rhyne et al., Pharmacotherapy. 2016), suggesting MAGL inhibitors may also have efficacy in treatment of migraine.
  • Mood and anxiety disorders are chronic, disabling conditions that impose cost to both patients and society.
  • the endocannabinoid system has received increasingly more intention in recent years.
  • a recent study by Bedse G et al., Transl Psychiatry. 2018 it is suggested that the use of MAGL inhibitors may have a beneficial effect in stress-related psychopathology.
  • depression selected from major depressive disorder, treatment-resistant depression, catatonic depression, melancholic depression, atypical depression, psychotic depression, perinatal depression, postpartum depression, bipolar depression, including bipolar I depression and bipolar II depression, and mild, moderate or severe depression.
  • Post-traumatic stress disorder is a trauma- or stress-related disorder. Patients having PTSD will have the symptoms of flashback of trauma, avoidance, hyperarousal, and negative cognitions/moods.
  • drugs that affect endocannabinoid signaling such as MAGL inhibitors
  • Contemplated methods for example, comprise exposing said enzyme to a compound described herein.
  • the ability of compounds described herein to modulate or inhibit MAGL is evaluated by procedures known in the art and/or described herein.
  • Another aspect of this disclosure provides methods of treating a disease associated with expression or activity of MAGL in a patient.
  • a compound of Formula (I), (la), (lb), (Ic), (Id), (le), or (If) is used in the treatment of a epilepsy/seizure disorder.
  • a compound of Formula (I), (la), (lb), (Ic), (Id), (le), or (If) is used in the treatment of a epilepsy/seizure disorder selected from acute repetitive seizures, temporal lobe epilepsy, Dravet syndrome, Lennox Gastaut syndrome or Angelman syndrome.
  • combination therapies for example, co-administering a compound of the invention and an additional active agent, as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
  • the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic coaction resulting from the combination of therapeutic agents.
  • Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually weeks, months or years depending upon the combination selected).
  • Combination therapy is intended to embrace administration of multiple therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
  • Substantially simultaneous administration is accomplished, for example, by administering to the subject a single formulation or composition, (e.g., a tablet or capsule having a fixed ratio of each therapeutic agent or in multiple, single formulations (e.g., capsules) for each of the therapeutic agents.
  • Sequential or substantially simultaneous administration of each therapeutic agent is affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
  • the therapeutic agents are administered by the same route or by different routes.
  • a first therapeutic agent of the combination selected is administered by intravenous injection while the other therapeutic agents of the combination are administered orally.
  • all therapeutic agents are administered orally or all therapeutic agents are administered by intravenous injection.
  • Combination therapy also embraces the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies.
  • the combination therapy further comprises a non-drug treatment
  • the non-drug treatment is conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved.
  • the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
  • the components of the combination are administered to a patient simultaneously or sequentially. It will be appreciated that the components are present in the same pharmaceutically acceptable carrier and, therefore, are administered simultaneously. Alternatively, the active ingredients are present in separate pharmaceutical carriers, such as conventional oral dosage forms, that are administered either simultaneously or sequentially.
  • a disclosed compound is coadministered with another therapeutic for pain such as an opioid, a cannabinoid receptor (CBi or CB?) modulator, a COX-2 inhibitor, acetaminophen, and/or a non-steroidal anti-inflammatory agent.
  • additional therapeutics e.g., for the treatment of pain that are co-administered, include morphine, pregabalin, gabapentin, codeine, hydromorphone, hydrocodone, oxymorphone, fentanyl, tramadol, and levorphanol.
  • contemplated therapeutics for co-administration include aspirin, naproxen, ibuprofen, salsalate, dif lunisal, dexibuprofen, fenoprofen, ketoprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, celecoxib, parecoxib, rimonabant, and/or etoricoxib.
  • 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (II) may be reacted with a primary amine (R may be a heteroaryl or a heterocycle) in the presence of a suitable base and solvent (e.g. DIPEA and THF) to form an intermediate of type III.
  • a suitable base and solvent e.g. DIPEA and THF
  • an intermediate of type II may be subjected to an acid halogenation reagent prior to step i) to form an acid halide.
  • the amide formation step i) is followed by a deprotection in step ii) carried out in a suitable acid and solvent (e.g. TFA and DCM) to provide an intermediate of type IV.
  • a suitable acid and solvent e.g. TFA and DCM
  • step iii) comprising a reaction with intermediate of type IV with l,l,l,3,3,3-hexafluoropropan-2-ol carried out in presence of a coupling agent such as CDI in an appropriate solvent (e.g. MeCN) to provide a compound of the present invention.
  • a coupling agent such as CDI in an appropriate solvent (e.g. MeCN) to provide a compound of the present invention.
  • amide linker is a tertiary amine (R may be a heteroaryl or a heterocycle).
  • R may be a heteroaryl or a heterocycle.
  • an intermediate of type III is subjected to an alkylation in step ia) to form an intermediate of type Illa.
  • An intermediate of type Illa may subsequently be subjected to deprotection step ii) and coupling step iii) as described in scheme 1 to provide a compound of the invention.
  • some compounds of the invention may be made by starting from commercially available t-butyl l-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate subjected to an aryl halide or a heteroaryl halide (X is a halogen; R is heteroaryl or phenyl) to form an intermediate of type VI.
  • X is a halogen; R is heteroaryl or phenyl
  • the analytical LC-MS system is equipped with Shimadzu LCMS-2020, PDA detector (operating at 254 nm), ELSD detector, and ESI-source operating in positive ion mode.
  • LC-conditions :
  • Method A The column is Kinetex EVO C18 50*3.0mm, 2.6pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 5mM NH4HCO3 (A) and ACN (B). The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method B The column is Kinetex EVO C18 50*3.0mm, 2.6pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 5mM NH4HCO3 (A) and ACN (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method C The column is Express C18 50*3.0mm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B). The retention times (t ) are expressed in minutes based on UV-trace at 254 nm.
  • Method D The column is HALO C18 30*3.0mm, 2 pm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 200 nm.
  • Method E The column is Poroshell HPH-C1850*3.0mm, 2.7pm operating at 40°C with 1.2 mL/min of a binary gradient consisting of water + 6.5 mM NH4HCO3 + Ammonia (pH - 10) (A) and ACN (B). The retention times (t ) are expressed in minutes based on UV-trace at 254 nm.
  • Method F The column is Express C18 50*3.0mm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method G The column is Kinetex EVO C18 50*3.0mm, 2.6pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 5mM NH4HCO3 (A) and ACN (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method H The column is Poroshell HPH-C1850*3.0mm, 2.7pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 5 mM NH4HCO3 (A) and acetonitrile (B). The retention times (t ) are expressed in minutes based on UV-trace at 254 nm.
  • Method I The column is CORTECS C18 50*2.1 mm, 2.7 pm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % trifluoroacetic acid (A) and acetonitrile + 0.05 % trifluoroacetic acid (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm. Gradient: 0.01 min 5% B
  • Method J The column is CORTECS C1850*2.1 mm, 2.7 pm operating at 40°C with 1.0 mL/min of a binary gradient consisting of water + 0.05 % trifluoroacetic acid (A) and acetonitrile + 0.05 % trifluoroacetic acid (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm. Gradient: 0.01 min 5% B
  • Method K The column is Express C18 50*3.0mm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B). The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method L The column is Kinetex EVO C18 50*3.0mm, 2.6pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 5mM NH4HCO3 (A) and ACN (B). The retention times (t ) are expressed in minutes based on UV-trace at 254 nm.
  • Method M The column is Poroshell HPH-C1850*3.0mm, 2.7pm operating at 40 °C with 1.2 mL/min of a binary gradient consisting of water + 6.5 mM NH4HCO3 + Ammonia (pH - 10) (A) and ACN (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method N The column is Kinelex XB-C1850*3.0mm, 2.6pm operating at 45 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05% TFA (A) and CAN + 0.05% TFA (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Method O The column is HALO C18 30*3.0mm, 2 pm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B).
  • the retention times (t ) are expressed in minutes based on UV-trace at 200 nm.
  • Method P The column is Express C18 50mm operating at 40 °C with 1.5 mL/min of a binary gradient consisting of water + 0.05 % TFA (A) and ACN + 0.05 % TFA (B).
  • the retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
  • Example 1 l,l,1333-Hexafluoropropan-2-yl ( ⁇ )l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate
  • Step 1 Synthesis of t-butyl l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • a vial was charged with 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (255 mg) (Nantong MYBio-pharm. Co., Ltd.), DMF (10 mg) and DCM (10 mL). Oxalyl chloride (189 mg) was added dropwise at 0 °C. The resulting solution was stirred for 2 h at 0 °C and concentrated under reduced pressure to provide t-butyl l-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate.
  • Another vial was charged with pyridin-3-amine (94.0 mg), THF (5 mL) and DIPEA (258 mg).
  • Step 3 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-(pyridin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • a vial was charged with l,l,l,3,3,3-hexafluoropropan-2-ol (489 mg), ACN (5 mL), 1,1'- carbonyldiimidazole (94.0 mg) and N-(pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide (112 mg).
  • the resulting solution was stirred overnight at 80 °C and quenched by adding water (10 mL).
  • the mixture was extracted with EtOAc (3 x 10 mL) and the organic layers were combined, washed with brine (3 x 10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • the crude product was purified by preparative HPLC using the following gradient conditions: 40% ACN/60% Phase A increasing to 70% ACN over 7 min, then to 100% ACN over 0.1 min, holding at 100% ACN for 1.9 min, then reducing to 40% ACN over 0.1 min, and holding at 40% for 1.9 min, on a Waters 2767-5 Chromatograph.
  • Example 2 1, 1,1,3# 3,3-Hexafluoropropan-2-yl (S)-l-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6- carboxylate and
  • Example 39 8 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(pyridin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate.
  • Example 3 was determined using vibrational circular dichroism (VCD) (Appl. Spectrosc. 65 (7), 699 (2011)). The spectrum was obtained with a ChirallR with DualPEM VCD-spectrometer and was compared with calculated values (methodology and basis set for DFT calculations - B3LYP / 6311Gdp with CPCM (chloroform)). VCD spectrum analysis of Example 3 to the calculated VCD spectrum for the (R)-enantiomer establishes Example 3 as the (R)-enantiomer and therefore Example 2 as the (S)-enantiomer.
  • VCD vibrational circular dichroism
  • Step 1 Synthesis of 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-l,6-dicarboxylate
  • Step 2 Synthesis of benzyl 6-azaspiro[2.5]octane-l-carboxylate hydrochloride
  • Step 4 Isolation of (S -l-benzyl 6-(l,l,l,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-l,6- dicarboxylate (Intermediate 2A) and (R -l-benzyl 6-(l,l,l,3,3,3-hexafluoropropan-2-yl) 6- azaspiro[2.5]octane-l,6-dicarboxylate (Intermediate 3A)
  • Step 5-1 Synthesis of (S)-6-(((l,l,l,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6- azaspiro[2.5]octane-l-carboxylic acid (Intermediate 2B)
  • Step 6-1 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate (Example 2)
  • Step 5-2 Synthesis of (R)-6-(((l,l,l,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6- azaspiro[2.5]octane-l-carboxylic acid (Intermediate 3B)
  • Step 6-2 Synthesis of l,l,1333-hexafluoropropan-2-yl (R)-l-(pyridin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate (Example 3)
  • Step 1 Synthesis of t-butyl l-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • N-(pyridazin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared with t-butyl 1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (180 mg) and TFA (5 mL) as described in Example 1, Step 2 to provide the title compound (125 mg).
  • Step 3 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl l-[(pyridazin-3-yl)carbamoyl]-6- azaspiro[2.5]octane-6-carboxylate
  • Example 5 15.3 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(pyridazin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate.
  • Example 6 10.1 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(pyridazin-3-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate.
  • Example 7 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )-l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of t-butyl l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6- carboxylate
  • N-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared with t-butyl l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (352 mg), TFA (1.5 mL) and DCM (3 mL) as described in Example 1, Step 2 to provide 500 mg (crude) of the title compound.
  • Step 3 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Example 8 l,l,1333-Hexafluoropropan-2-yl (S)-l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate and
  • Example 9 l,l,1333-Hexafluoropropan-2-yl (R)-l-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Example s 13 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-((tetrahydro-2H-pyran-4- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Example 9 15.4 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-((tetrahydro-2H-pyran-4- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Example 10 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )l-(methyl(pyrazin-2-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of t-butyl l-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • t-Buty I l-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t- butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (500 mg), DCM (10 mL), DMF (14.0 mg), oxalyl chloride (249 mg), pyrazin-2-amine (186 mg), pyridine (464 mg) and t-butyl l-(carbonochloridoyl)-6- azaspiro[2.5]octane-6-carboxylate as described in Example 1, Step 1 to provide the title compound (190 mg).
  • Step 2 Synthesis of t-butyl l-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • N-methyl-N-(pyrazin-2-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared from t-butyl 1- (methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (140 mg), TFA (3 mL) and DCM (3 mL) as described in Example 1, Step 2 to provide the title compound (99.7 mg).
  • Step 4 Synthesis of l,l,1333-hexafluoropropan-2-yl ( ⁇ )l-(methyl(pyrazin-2-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • a vial was charged with 1,1,1, 3,3, 3-hexafluoropropan-2-ol (102 mg, 0.606 mmol, 1.50 equiv), DCM (10 mL) and triphosgene (67.8 mg). DIPEA (156 mg) was added at 0 °C. The resulting solution was stirred for 2 h at room temperature, then N-methyl-N-(pyrazin-2-yl)-6-azaspiro[2.5]octane-l- carboxamide (99.7 mg) was added. The resulting solution was stirred overnight at room temperature and then quenched with water (10 mL). The solution was extracted with DCM (3 x 10 mL) and the organic layers were combined, washed with brine (3 x 10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound.
  • Example 11 l,l,l,3,3,3-Hexafluoropropan-2-yl (R)-l-(methyl(pyrazin-2-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 1 and
  • Example 12 l,l,1333-Hexafluoropropan-2-yl (S)-l-(methyl(pyrazin-2-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 10 The racemic mixture prepared in Example 10 was separated into the two enantiomers by preparative chiral-HPLC (Column: CHIRALPAK IA Column 2*25cm, 5pm; Mobile Phase A: Hex--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL/min; Gradient: 30% B to 30% B over 11 min; Detector, UV220 & 254nm) to afford:
  • Example 11 12.5 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(methyl(pyrazin-2- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 12 12.1 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(methyl(pyrazin-2- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 11 The absolute configurations of Examples 11 and 12 were determined in a similar manner as in Example 3, wherein resynthesis of the final compound using an intermediate with known absolute configuration allowed for the assignment of the absolute configuration of the final products (Example 11 and Example 12). In the end it was determined that the first eluting enantiomer was the (R) enantiomer (Example 11), and therefore Example 12 as the (S)-enantiomer.
  • Example 13 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )-l-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane- 6-carboxylate
  • Step 1 Synthesis of 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-l,6-dicarboxylate
  • Step 2 Synthesis of benzyl 6-azaspiro[2.5]octane-l-carboxylate
  • Step 3 Synthesis of 1-benzyl 6-(l,l,1333-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-l,6- dicarboxylate
  • Step 4 Synthesis of 6-(((l,l,1333-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-l- carboxylic acid
  • Step 5 Synthesis of l,l,1333-hexafluoropropan-2-yl ( ⁇ )l-(isoxazol-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Example 14 l,l,l,3,3,3-Hexafluoropropan-2-yl (S)-l-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane- 6-carboxylate peak 1 and
  • Example 15 l,l,l,3,3,3-Hexafluoropropan-2-yl (R)-l-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane- 6-carboxylate peak 2
  • the racemic mixture prepared in Example 10 (70 mg) was separated into the two enantiomers by preparative chiral HPLC (Column: CHIRALPAK IG, 2*25cm,5pm; Mobile Phase A: Hex(0.5% 2M NH 3 -MeOH)-HPLC, Mobile Phase B: IPA-HPLC; Flow rate: 20 mL/min; Gradient: 20% B to 30% B over 7.5 min; Detector, UV220 & 254nm) to afford:
  • Example 14 15.0 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-(isoxazol-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 15 9.7 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-(isoxazol-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 14 The absolute configurations of Examples 14 and 15 were determined in a similar manner as in Example 3, wherein resynthesis of the final compound using an intermediate with known absolute configuration allowed for the assignment of the absolute configuration of the final products (Example 14 and Example 15). In the end it was determined that the second eluting enantiomer was the (R) enantiomer (Example 15), and therefore Example 14 as the (S)-enantiomer.
  • Example 16 l,l,1333-Hexafluoropropan-2-yl ( ⁇ )-l-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-
  • Step 1 Synthesis of t-butyl l-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Step 2 Synthesis of t-butyl l-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-
  • N-(2-(trifluoromethyl)pyrimidin-4-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared with t-butyl l-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (240 mg), 1,4-dioxane (4 mL) and concentrated hydrochloric acid (1 mL) as described in Example 13, Step 2 to provide the title compound (180 mg).
  • Step 4 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )-l-((2-(trifluoromethyl)pyrimidin-4- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Example 17 l,l,l,3,3,3-Hexafluoropropan-2-yl (S)-l-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)- 6-azaspiro[2.5]octane-6-carboxylate peak 1 and
  • Example 18 l,l,l,3,3,3-Hexafluoropropan-2-yl (R)-l-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)- 6-azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 16 The racemic mixture prepared in Example 16 was separated into the two enantiomers by preparative chiral HPLC (Column: CHIRALPAK AD-H, 2*25cm,5pm; Mobile Phase A:Hex-HPLC, Mobile Phase B: EtOH-HPLC; Flow rate:20 mL/min; Gradient:5% B to 5% B over 11 min; UV220/254 nm) to afford:
  • Example 17 15.8 mg l,l,l,3,3,3-hexafluoropropan-2-yl (S)-l-((2-(trifluoromethyl)pyrimidin-4- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 18 17.2 mg l,l,l,3,3,3-hexafluoropropan-2-yl (R)-l-((2-(trifluoromethyl)pyrimidin-4- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 17 and 18 were determined in a similar manner as in Example 3, wherein resynthesis of the final compound using an intermediate with known absolute configuration allowed for the assignment of the absolute configuration of the final products (Example 17 and Example 18). In the end it was determined that the second eluting enantiomer was the (R) enantiomer (Example 18), and therefore Example 17 as the (S)-enantiomer.
  • Example 19 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )-l-((6-(dimethylphosphoryl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of t-butyl l-((6-iodopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Step 2 Synthesis of t-butyl l-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 3 Synthesis of N-(6-(dimethylphosphoryl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide hydrochloride
  • N-(6-(dimethylphosphoryl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide hydrochloride was prepared from t-butyl l-[[6-(dimethylphosphoryl)pyridin-3-yl]carbamoyl]-6-azaspiro[2.5]octane-6- carboxylate (560.00 mg), DCM (5.00 mL), and HCI(g), (4 M in 1,4-dioxane, 5.00 mL, 20 mmol) as described in Example 13, Step 2 to provide the title compound (400 mg). The crude product was used directly in the next step directly without further purification. LCMS (ESI, m/z): 308 [M-HCI+H] + .
  • Step 4 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )-l-((6-(dimethylphosphoryl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Example 20 l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((6-(dimethylphosphoryl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1
  • Example 21 l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((6-(dimethylphosphoryl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 20 135.2 mg l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6-
  • Example 21 122.5 mg l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6-
  • Example 22 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )-l-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane- 6-carboxylate
  • Step 1 Synthesis of t-butyl l-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate
  • Step 2 Synthesis of t-butyl l-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • N-(pyridin-4-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared from t-butyl l-(pyridin-4- ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (360 mg), DCM (5 mL), and HCI (gas)/l,4-dioxane (3 mL) as described in Example 13, Step 2 to provide the title compound (200 mg).
  • Step 4 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )-l-(pyridin-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Example 23 l,l,1333-Hexafluoropropan-2-yl (R or S)-l-(pyridin-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 1 and
  • Example 24 l,l,1333-Hexafluoropropan-2-yl (R or S)-l-(pyridin-4-ylcarbamoyl)-6- azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 22 The racemic mixture prepared in Example 22 was separated into the two enantiomers by chiral HPLC (CHIRALPAK IF, 2*25cm,5pm; Mobile Phase A: Hex (lOmM NH 3 -MeOH), Mobile Phase B: EtOH- HPLC; Flow rate:15 mL/min; Gradient:5% B to 5% B over 15 min; UV220/254 nm) to afford:
  • Example 23 32.9 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-(pyridin-4-ylcarbamoyl)- 6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 24 32.2 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-(pyridin-4-ylcarbamoyl)- 6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 25 l,l,1333-Hexafluoropropan-2-yl ( ⁇ )l-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of t-butyl l-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate
  • t-Butyl l-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t- butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (600 mg, 2.34 mmol, 1.00 equiv), HATU (1069 mg, 2.80 mmol, 1.20 equiv), DIPEA (15.2 mg, 11.2 mmol, 5.00 equiv), NH4CI (620 mg, 11.7 mmol, 5.00 equiv) in DMF (10 mL) as described in Example 19, Step 1 to afford t-butyl l-carbamoyl-6- azaspiro[2.5]octane-6-carboxylate (500 mg).
  • LCMS ES
  • Step 2 Synthesis of t-butyl l-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6- carboxylate
  • N-(tetrahydro-2H-pyran-4-carbonyl)-6-azaspiro[2.5]octane-l-carboxamide was prepared from t-butyl l-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (230 mg), DCM (5 mL), and a solution of HCI (gas)/l,4-dioxane (3 mL) as described in Example 13, Step 2 to provide of A/-(tetrahydro-2/-/-pyran-4-carbonyl)-6-azaspiro[2.5]octane-l-carboxamide (130 mg).
  • LCMS (ESI, m/z): 267[M+H] + .
  • Step 4 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-((tetrahydro-2H-pyran-4- carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )l-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate was prepared from A/-(tetrahydro-2/-/-pyran-4-carbonyl)-6- azaspiro[2.5]octane-l-carboxamide (200 mg), CDI (146 mg) ACN (5 mL), DIPEA (489 mg, 3.79 mmol, 2.00 equiv) and l,l,l,3,3,3-hexafluoroprop
  • Example 26 Synthesis of l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((tetrahydro-2H-pyran-4- carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1
  • Example 27 Synthesis of l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((tetrahydro-2H-pyran-4- carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 25 The racemic mixture prepared in Example 25 (100 mg) was separated into the two enantiomers by chiral HPLC (CHIRALPAK IF, 2*25cm,5pm; Mobile Phase A: Hex (lOmM NHs-MeOH), Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL/min; Gradient:10% B to 10% B over 25 min; UV220/254 nm) to afford:
  • Example 26 41.5 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((tetrahydro-2/-/-pyran-4- carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 27 24.7 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((tetrahydro-2/-/-pyran-4- carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 28 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )l-((6-(lH-pyrazol-l-yl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 3 Synthesis of t-butyl l-((6-(lH-pyrazol-l-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6- carboxylate
  • t-butyl l-((6-(lH-Pyrazol-l-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6- was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (300 mg), N-(5-aminopyridin-2- yl)acetamide (245 mg), EDCI (248 mg), HOBT (159 mg), and TEA (356 mg) in DCM (3 mL) as described in Example 7, Step 1 to provide t-butyl l-((6-(lH-pyrazol-l-yl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate (300 mg).
  • Step 4 Synthesis of N-(6-(lH-pyrazol-l-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide
  • N-(6-(lH-Pyrazol-l-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared from t- butyl l-((6-(lH-pyrazol-l-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (300 mg), DCM (6 mL) and HCI(g) (3 mL) as described in Example 13, Step 2 to provide N-(6-(lH-pyrazol-l- yl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide (200 mg).
  • Step 5 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-((6-(lH-pyrazol-l-yl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • Example 29 l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((6-(lH-pyrazol-l-yl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1
  • Example 30 l,l,1333-Hexafluoropropan-2-yl (R or S)-l-((6-(lH-pyrazol-l-yl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 29 84.2 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6-(lH -pyrazol-1- yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 30 86.1 mg l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6-(lH-pyrazol-l-yl)pyridin- 3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 31 l,l,1333-Hexafluoropropan-2-yl ( ⁇ )l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of 5-amino-N-methylpicolinamide
  • Methyl 5-aminopicolinate 500 mg was added to a solution of MeNH? (204 mg, 6.58 mmol, 2.00 equiv) in EtOH (5 mL). The resulting solution was stirred at 80 °C overnight at room temperature and then quenched with water (10 mL). The resulting solution was extracted with EtOAc (3 x 20 mL) and the organic layers were combined, washed with brine (1 x 20 mL), dried over anhydrous NazSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to provide 5-amino-N-methylpicolinamide (400 mg). LCMS (ESI, m/z): 152 [M+H] + .
  • Step 2 Synthesis of t-butyl l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6- carboxylate
  • t-Butyl l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-l-carboxylic acid (300 mg), 5-amino-N- methylpicolinamide (231 mg), HATU (671 mg), and DIPEA (455 mg) in DMF (5 mL) as described in Example 19, Step 1 provide t-butyl l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate (210 mg).
  • N-(6-(Methylcarbamoyl)pyridin-3-yl)-6-azaspiro[2.5]octane-l-carboxamide was prepared from t-butyl l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (210 mg) and HCI(g) (2 mL) in DCM (4 mL) as described in Example 13, Step 2 to provide N-(6-
  • Step 4 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl l-((6-(methylcarbamoyl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate
  • l,l,l,3,3,3-Hexafluoropropan-2-yl l-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6- azaspiro[2.5]octane-6-carboxylate was prepared from N-(6-(methylcarbamoyl)pyridin-3-yl)-6- azaspiro[2.5]octane-l-carboxamide (140 mg), ACN (3 mL), l,l'-carbonyldiimidazole (102mg), DIPEA (188 mg) and l,l,l,3,3,3,
  • Example 32 l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((6-(methylcarbamoyl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1
  • Example 33 l,l,l,3,3,3-Hexafluoropropan-2-yl (R or S)-l-((6-(methylcarbamoyl)pyridin-3- yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2
  • Example 32 33.1 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6- (methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 1.
  • Example 33 31.8 mg of l,l,l,3,3,3-hexafluoropropan-2-yl (R or S)-l-((6- (methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2.
  • Example 34 l,l,l,3,3,3-Hexafluoropropan-2-yl ( ⁇ )l-(4-cyclopropylpiperazine-l-carbonyl)-6- azaspiro[2.5]octane-6-carboxylate
  • Step 1 Synthesis of t-butyl l-(4-cyclopropylpiperazine-l-carbonyl)-6-azaspiro[2.5]octane-6- carboxylate
  • Step 2 Synthesis of (4-cyclopropylpiperazin-l-yl)(6-azaspiro[2.5]octan-l-yl)methanone
  • Step 3 Synthesis of l,l,l,3,3,3-hexafluoropropan-2-yl ( ⁇ )l-(4-cyclopropylpiperazine-l-carbonyl)-6- azaspiro[2.5]octane-6-carboxylate
  • the crude product was purified by preparative HPLC using the following gradient conditions: 20% CH3CN/80% Phase A increasing to 80% CH3CN over 10 min, then to 100% CH3CN over 0.1 min, holding at 100% CH3CN for 1.9 min, then reducing to 20% CH3CN over 0.1 min, and holding at 20% for 1.9 min, on a Waters 2767-5 Chromatograph.
  • Examples 35-189 were prepared by similar procedures as described in Examples 1-34. Absolute configuration of Examples 36, 105, 118, 142, 151, 162, and 174 were determined in a similar manner as example 3, wherein resynthesis of the final compound using an intermediate with known absolute configuration allowed for the assignment of the absolute configuration of the final products. The stereochemistry of the corresponding (S)-enantiomers (Examples 37, 106, 117, 141, 150, 163 and 175) were assigned as described above for Example 12, 14, and 17.
  • PC3 human cell membrane proteomes (50 pL, 2.0 mg/mL total protein concentration) were preincubated with varying concentrations of inhibitors at 37 °C. After 30 min, the ABPP probe JW912- Bodipy (1.0 pL, 50 pM in DMSO) was added and the mixture was incubated for 30 min at room temperature. Reactions were quenched with SDS loading buffer (15 pL - 4X) and run on SDS-PAGE. Following gel imaging, serine hydrolase activity was determined by measuring fluorescent intensity of gel bands corresponding to MAGL using Image! 1.43u software. Intensities were converted to percent enzyme activity by normalizing to DMSO controls. IC50 values were determined by fitting percent enzyme activities to a non-linear regression, 4-parameter, sigmoidal dose response function in Prism GraphPad.
  • HEK293 cell lysates expressing recombinant human MAGL enzyme and 4-nitrophenyl acetate (pNPA) substrate were diluted separately in 50 mM HEPES (pH 7.0) containing 200 mM KCI and 1 mM EDTA. Lysates (50 pL, ⁇ 1.2 pg total protein) were preincubated with varying concentrations of inhibitors at 25 °C. After 30 min, 2X pNPA substrate (50 pL, 2.5 mM) was added and the rate of substrate turnover was monitored by measuring the increase in absorbance at wavelength 405 nm for 20 minutes at 25 °C using a Biotek Neo2 plate reader. The mean velocity was converted to percent enzyme activity following background subtraction and normalization to DMSO controls. IC50 values were determined by fitting percent enzyme activities to a non-linear regression, 4-parameter, sigmoidal dose response function in Prism GraphPad.
  • Inhibitors were administered to wild-type C57BI/6J by oral gavage in a vehicle of polyethylene glycol. Each animal was sacrificed 4 h following administration and brain proteomes were prepared and analyzed according to previously established methods (See Niphakis, M. J., et al. (2011) ACS Chem.
  • Example 191 Effects of Acute Treatment in the Rat Formalin Paw Model of Inflammatory Pain
  • formalin is administered into the right hand paw of a rat in order to induce pain (observed by hind limb licking duration and frequency).
  • Test compounds are administered in order to evaluate their efficacy in reducing the frequency of hind limb licking, which is suggested to translate into an alleviation in pain such as acute and/or chronic pain in patients.
  • Male Sprague Dawley rats were divided into three cohorts to enable testing in the La borasTM equipment to be carried out over three days in a balanced design to give treatment groups of 10.
  • male Sprague Dawley rats were weighed, tail marked and dosed orally with vehicle, test compound (0.1, 0.3, 0.6, 1, 3 or 10 mg/kg) or pregabalin (30 mg/kg) 4 h pre-test using a 5 mL/kg dosing volume.
  • test compound 0.1, 0.3, 0.6, 1, 3 or 10 mg/kg
  • pregabalin 30 mg/kg 4 h pre-test using a 5 mL/kg dosing volume.
  • the vehicle used was 0.5% methylcellulose in water and for Example 8 the vehicle used was 20% HP-b-CD. Up to six animals were dosed at a time.
  • rats received an intraplantar injection of 50 pL of a 2.5% v/v formalin solution into the right hind paw. Rats were immediately placed into the LaborasTM cages and data acquisition started. The primary measures recorded by LaborasTM for the formalin paw model are hind limb licking duration and frequency.
  • Locomotion is also reported as maximum speed, average speed when moving or over the whole-time bin and distance travelled. After 40 min, when data acquisition was complete, rats were removed from the cages.
  • rats On removal from the test cages, rats were anaesthetised with the gaseous anaesthetic isoflu- rane (5% v/v isoflurane in oxygen) and blood samples were collected by cardiac puncture. Brains were then removed, rinsed in phosphate buffered saline (PBS), hemi-sected and frozen separately in liquid nitrogen.
  • PBS phosphate buffered saline
  • Example 6 As shown in Fig 1, administration of Example 6 at 0.6 mg/kg, 3 mg/kg and 10 mg/kg showed statistically significant reduction in the measure of spontaneous pain (hind limb licking frequency) in the early and/or late phases of the test. As shown in Fig 2, administration of Example 8 at 1 mg/kg, 3 mg/kg and 10 mg/kg showed statistically significant reduction in the measure of spontaneous pain (hind limb licking frequency) in both early and late phases of the test and Example 8 additionally at 0.3 mg/kg and 0.6 mg/kg demonstrated a statistically significant reduction in the measure of spontaneous pain in the late phase.
  • Rats were individually assessed for production of a tonic hind limb extensor seizure following a single corneally delivered electroshock of 0.3 second duration, using an 'up and down method' of shock titration (Kimball AW et al., 1957).
  • the first rat within a treatment group was given a shock at the expected or estimated CC50 current (current producing tonic hind limb extensor seizures in 50% of animals).
  • the stimulus intensity was lowered or raised in log 0,06 : 10 A (l+x*0,06) mA intervals if the preceding rat did or did not show tonic hind limb extension, respectively. This procedure was continued for all rats within a treatment group. Induction of seizure was measured as an all-or-nothing effect scored as either present (+) or absent (0) for each animal.
  • Kainic acid is an analog of the excitatory neurotransmitter, glutamate and acts as an agonist of kainic acid receptors. After systemic injection, kainic acid induces prolonged excitatory responses with many of the features of human temporal lobe epilepsy.
  • Rats placed in individual Plexiglas cages (33 x 21 x 18 cm), are injected with kainic acid (20 mg/kg i.p.). The occurrences of the following symptoms are noted over a 120-minute period 30 minutes after kainic acid injection: forelimb clonus, rearings and rearings with falling, clonic convulsions, tonic convulsions and death. The presence of each symptom and the latencies to the first appearance of the symptoms are measured. The number of forelimb clonus is counted.
  • test substances will be evaluated at multiple doses, administered p.o. 240 minutes before the test, and compared with the corresponding vehicle control group (Group 2, administered with 10% HP-b-CD in distilled water, p.o. 240 minutes before the test).
  • Example 6 was evaluated at 0.3, 1, 3 and 10 mg/kg, and Example 8 was evaluated at 1, 3 and 10 mg/kg, administered p.o. 4 hours before the test, and compared with a vehicle control group (administered with 10% HP-b-CD, p.o. 4 hours before the test).
  • Example 8 was evaluated at 1, 3 and 10 mg/kg, administered p.o. 4 hours before the test, and compared with a vehicle control group (administered with 10% HP-b-CD, p.o. 4 hours before the test).
  • Diazepam (16 mg/kg) used as reference substance was administered p.o. 60 minutes before the test (0.5% HP-b-CD) and was compared with vehicle controls.
  • Quantal data were analyzed by comparing treated groups with vehicle control using Fisher's Exact Probability tests.
  • Example 6 over the dose-range 0.3-10 mg/kg and Example 8 over the dose-range 1-10 mg/kg in the kainic acid seizure test in the rat.
  • the magnitude of the effects for Example 6 and Example 8 compounds at middle-high doses were close to those observed with the reference substance, Diazepam.
  • test compound was formulated as a simple suspension, in 0.5% HPMC in water, then administered by oral gavage (5 mg/kg, 5 mL/kg).
  • oral gavage 5 mg/kg, 5 mL/kg.
  • rats were sacrificed, and terminal blood and brain samples were taken. Blood was obtained via cardiac puncture (0.1 mL) and was added into 0.4 mL CH3CN for precipitation immediately. The samples were stored at -75 +/- 15 °C prior to analysis. Brain tissue samples were collected after animals were fully exsanguinated, and the tissues were washed with cold saline quickly.
  • brain sections were immediately frozen in liquid nitrogen and stored at -75 +/- 15 °C prior to analysis.
  • Blood and brain samples were analyzed by LC/MS/MS using an optimized analytical method. Concentrations of test compound in blood and brain were quantified against matrix matched calibration standards.
  • the total blood, plasma, and brain concentration data are presented in Table 2 alongside the calculated brain K p (total brain concentratiomtotal plasma concentration ratio), the calculated brain k p , uu (unbound brain concentratiomunbound plasma concentration ratio), the free fractions in rat plasma and brain, and the in vitro rat blood to plasma distribution profile.
  • the total plasma concentration data were calculated from the total blood concentration data using rat blood to plasma ratio which was measured in vitro (1 pM test compound).
  • test articles The kinetic solubility of test articles was determined in PBS at pH 2.0 and pH 7.4 in duplicate.
  • a stock solution of test compound in DMSO (10 mM) was incubated at RT for 2 hours with shaking at 1,100 RPM.
  • the sample was then filtered using a vacuum manifold, diluted, and analyzed by LC- MS/MS. Chromatographic conditions: Phenomenex Synergi 4p Hydro-PR 80A column (2.0 x 30 mm) coupled with pre-guard column; mobile phase - 0.1% formic acid in acetonitrile and 0.1% formic acid in water; flowrate - 0.65 mL/min; column temperature - 40 °C; injection volume: 3 pL.
  • Mass conditions Turbo spray ion source; ESI ionization model; MRM scan type; Collison gas - 6 L/min; Curtain gas - 30 L/min; Nebulize gas - 50 L/min; Auxiliary gas - 50 L/min; Temperature - 500 degrees C; Ion spray voltage - +5500 v (positive MRM).
  • the filtered solution was analyzed and quantified against a standard of known concentration in DMSO using UPLC coupled with mass spectral peak identification and quantitation. Solubility values of the test articles were calculated using Microsoft Excel as follows (DF is the dilution factor):
  • thermodynamic solubility (thermodynamic)
  • the thermodynamic solubility of test article was determined in PBS at pH 7.4 in duplicate.
  • the test article (1.5 mg) in PBS was incubated for 24 hours at RT with shaking at 1100 rpm.
  • Sample was then filtered using a vacuum manifold, diluted, and analyzed by LC-MS/MS. Chromatographic conditions: Phenomenex Synergi 4p Hydro-PR 80A column (2.0x30 mm) coupled with pre-guard column; mobile phase - 0.1% formic acid in acetonitrile and 0.1% formic acid in water; flowrate - 0.65 mL/min; column temperature - 40 degrees C; injection volume: 10 pL. obile phase: 0.1% formic acid in acetonitrile (A) and 0.1% formic acid in water (B)
  • Mass conditions Turbo spray ion source; ESI ionization model; MRM scan type; Collison gas - 6 L/min; Curtain gas - 30 L/min; Nebulize gas - 50 L/min; Auxiliary gas - 50 L/min; Temperature - 500 degrees C; Ion spray voltage - +5500 v (positive MRM).
  • thermodynamic solubility data are presented in Table 4.
  • Example 197 In vitro human hepatocyte stability
  • Conversion of the in vitro ti/zfin min) into the scale-up unbound intrinsic clearance (Scaled-up unbound CLint, in mL/min/kg) was done using the following equation (mean of duplicate determinations), with data shown in Table 5: Scaled-up unbound CLint- kV/N x scaling factor.
  • V - incubation volume (0.25 mL); N - number of hepatocytes per well (0.125 x 10 5 cells).
  • Scaling factors for in vivo intrinsic clearance prediction are listed below:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2021/081522 2020-11-13 2021-11-12 A magl inhibitor Ceased WO2022101412A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
KR1020237015365A KR20230107225A (ko) 2020-11-13 2021-11-12 Magl 억제제
SI202130311T SI4244208T1 (sl) 2020-11-13 2021-11-12 Zaviralec magl
IL301818A IL301818B1 (en) 2020-11-13 2021-11-12 magl inhibitor
US18/252,611 US20240018120A1 (en) 2020-11-13 2021-11-12 Magl inhibitors
PL21811018.7T PL4244208T3 (pl) 2020-11-13 2021-11-12 Inhibitor magl
CN202180073621.0A CN116547274B (zh) 2020-11-13 2021-11-12 Magl抑制剂
JP2023524567A JP2023549051A (ja) 2020-11-13 2021-11-12 Ｍａｇｌ阻害剤
MX2023005576A MX2023005576A (es) 2020-11-13 2021-11-12 Un inhibidor de magl.
RS20250496A RS66839B1 (sr) 2020-11-13 2021-11-12 Magl inhibitor
HRP20250644TT HRP20250644T1 (hr) 2020-11-13 2021-11-12 Magl inhibitor
CR20230203A CR20230203A (es) 2020-11-13 2021-11-12 Un inhibidor de magl
UAA202301351A UA130186C2 (uk) 2020-11-13 2021-11-12 Інгібітор magl
EP25166976.8A EP4574150A3 (en) 2020-11-13 2021-11-12 A magl inhibitor
FIEP21811018.7T FI4244208T3 (fi) 2020-11-13 2021-11-12 Magl:n estäjä
MA62148A MA62148B1 (fr) 2020-11-13 2021-11-12 Inhibiteur de magl
CN202512011225.8A CN121824488A (zh) 2020-11-13 2021-11-12 Magl抑制剂
LTEPPCT/EP2021/081522T LT4244208T (lt) 2020-11-13 2021-11-12 Magl inhibitorius
EP21811018.7A EP4244208B1 (en) 2020-11-13 2021-11-12 A magl inhibitor
AU2021379081A AU2021379081A1 (en) 2020-11-13 2021-11-12 A magl inhibitor
CA3196119A CA3196119A1 (en) 2020-11-13 2021-11-12 A magl inhibitor
ES21811018T ES3025484T3 (en) 2020-11-13 2021-11-12 A magl inhibitor
DK21811018.7T DK4244208T3 (da) 2020-11-13 2021-11-12 Magl-hæmmer
ZA2023/04134A ZA202304134B (en) 2020-11-13 2023-04-04 A magl inhibitor
CONC2023/0004649A CO2023004649A2 (es) 2020-11-13 2023-04-14 Un inhibidor de magl
SA523440403A SA523440403B1 (ar) 2020-11-13 2023-04-17 Magl مثبط
JOJO/P/2023/0091A JOP20230091A1 (ar) 2020-11-13 2023-05-01 مثبط magl
DO2023000086A DOP2023000086A (es) 2020-11-13 2023-05-02 Un inhibidor de magl

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113662P 2020-11-13 2020-11-13
US63/113,662 2020-11-13

Publications (1)

Publication Number Publication Date
WO2022101412A1 true WO2022101412A1 (en) 2022-05-19

Family

ID=78709459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/081522 Ceased WO2022101412A1 (en) 2020-11-13 2021-11-12 A magl inhibitor

Country Status (33)

Country Link
US (2) US11434222B2 (https=)
EP (2) EP4244208B1 (https=)
JP (1) JP2023549051A (https=)
KR (1) KR20230107225A (https=)
CN (2) CN116547274B (https=)
AR (1) AR124057A1 (https=)
AU (1) AU2021379081A1 (https=)
CA (1) CA3196119A1 (https=)
CL (1) CL2023001339A1 (https=)
CO (1) CO2023004649A2 (https=)
CR (1) CR20230203A (https=)
DK (1) DK4244208T3 (https=)
DO (1) DOP2023000086A (https=)
ES (1) ES3025484T3 (https=)
FI (1) FI4244208T3 (https=)
GE (2) GEP20257794B (https=)
HR (1) HRP20250644T1 (https=)
HU (1) HUE071543T2 (https=)
IL (1) IL301818B1 (https=)
JO (1) JOP20230091A1 (https=)
LT (1) LT4244208T (https=)
MA (1) MA62148B1 (https=)
MX (1) MX2023005576A (https=)
PL (1) PL4244208T3 (https=)
PT (1) PT4244208T (https=)
RS (1) RS66839B1 (https=)
SA (1) SA523440403B1 (https=)
SI (1) SI4244208T1 (https=)
TW (1) TWI904281B (https=)
UA (1) UA130186C2 (https=)
UY (1) UY39516A (https=)
WO (1) WO2022101412A1 (https=)
ZA (1) ZA202304134B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213854A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
US12286421B2 (en) 2021-12-29 2025-04-29 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (MAGL)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
WO2019046330A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429991A (en) * 2005-09-07 2007-03-14 Alan Barrows Water powered impulsive unit
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
JP6404717B2 (ja) * 2012-03-02 2018-10-17 ジェネンテック， インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017083867A1 (en) * 2015-11-12 2017-05-18 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110198944A (zh) * 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
KR20250005229A (ko) * 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
WO2019046330A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
BEDSE G ET AL., TRANSL PSYCHIATRY, 2018
BEN-ARI ET AL., NEUROSCIENCE, vol. 6, 1981, pages 1361 - 1391
BLANKMAN ET AL., CHEM BIOL., 2007
BURCKHARDT ET AL.: "The fibromyalgia impact questionnaire: development and validation", J RHEUMATOL, 1991, pages 728 - 33
COLLIN ET AL., EUR J NEUROL, 2007
COLLIN ET AL., NEUROL RES, 2010
GIL-ORDONEZ ET AL., BIOCHEM PHARMACOL, 2018
GRABNER ET AL., PHARMACOL THER, 2017
HILL ET AL., NEUROPSYCHOPHARMACOLOGY, 2018
ILYASOV ET AL., FRONT NEUROSCI, 2018
KATONAFREUND, PHYSIOL REV, 2009
LANGFORD ET AL., J NEUROL, 2013
LONG, J. Z. ET AL., CHEM. BIOL., vol. 5, pages 37 - 44
MEASE ET AL., THE JOURNAL OF RHEUMATOLOGY, vol. 35, no. 1, January 2008 (2008-01-01), pages 20 - 30
MULVIHILL ET AL., LIFE SCI, 2013
NIPHAKIS, M. J. ET AL., ACS CHEM. NEUROSCI, 2011
NOMURA ET AL., SCIENCE, 2011
PRYCE ET AL., HANDB EXP PHARMACOL, vol. 231, 2015, pages 213 - 31
RHYNE ET AL., PHARMACOTHERAPY, 2016
ROG ET AL., NEUROLOGY, 2005
SARCHIELLI ET AL., NEUROPSYCHOPHARMACOLOGY, 2007
SKRABEK ET AL., J PAIN, 2008
SUGAYA ET AL., CELL REP, 2016
TURCOTTE ET AL., CELL MOL LIFE SCI, 2016
TURCOTTE ET AL., PAIN MED, 2015
WARE, ANESTH ANALG, vol. 110, no. 2, 2010, pages 604 - 10
WHITING ET AL., JAMA, 2015
ZAJICEK ET AL., LANCET, 2003

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286421B2 (en) 2021-12-29 2025-04-29 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (MAGL)
WO2023213854A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
US12378219B2 (en) 2022-05-04 2025-08-05 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor

Also Published As

Publication number Publication date
IL301818A (en) 2023-06-01
US20220153721A1 (en) 2022-05-19
SI4244208T1 (sl) 2025-07-31
EP4244208A1 (en) 2023-09-20
IL301818B1 (en) 2026-02-01
CA3196119A1 (en) 2022-05-19
ES3025484T3 (en) 2025-06-09
PT4244208T (pt) 2025-05-22
GEP20257794B (en) 2025-09-10
TWI904281B (zh) 2025-11-11
CR20230203A (es) 2023-06-14
MX2023005576A (es) 2023-05-29
HUE071543T2 (hu) 2025-09-28
EP4244208B1 (en) 2025-04-02
DK4244208T3 (da) 2025-05-26
PL4244208T3 (pl) 2025-06-30
TW202229255A (zh) 2022-08-01
KR20230107225A (ko) 2023-07-14
EP4574150A2 (en) 2025-06-25
AR124057A1 (es) 2023-02-08
DOP2023000086A (es) 2023-06-30
FI4244208T3 (fi) 2025-06-10
RS66839B1 (sr) 2025-06-30
AU2021379081A1 (en) 2023-05-18
ZA202304134B (en) 2024-08-28
JP2023549051A (ja) 2023-11-22
SA523440403B1 (ar) 2024-10-10
JOP20230091A1 (ar) 2023-05-01
UY39516A (es) 2022-05-31
CN116547274A (zh) 2023-08-04
EP4574150A3 (en) 2025-08-20
LT4244208T (lt) 2025-06-10
US20240018120A1 (en) 2024-01-18
US11434222B2 (en) 2022-09-06
MA62148B1 (fr) 2025-05-30
UA130186C2 (uk) 2025-12-10
CL2023001339A1 (es) 2023-10-20
HRP20250644T1 (hr) 2025-07-18
CN116547274B (zh) 2026-02-13
CN121824488A (zh) 2026-04-10
GEAP202516246A (en) 2025-04-10
CO2023004649A2 (es) 2023-05-08

Similar Documents

Publication Publication Date Title
AU2017250302B2 (en) Inhibitors of activin receptor-like kinase
AU2017353310B2 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors
RU2603140C2 (ru) Соединения имидазотриазинона
TWI829676B (zh) 噁二唑暫時受體電位通道抑制劑
WO2022101412A1 (en) A magl inhibitor
KR20170066417A (ko) Pde1 억제제로서의 트리아졸로피라지논
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
CN114786673A (zh) Cdk抑制剂及其作为药物的用途
CA2820262A1 (en) Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
EP4072679A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
AU2017353313A1 (en) (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
JP2019532983A (ja) ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン化合物
HK40100721B (en) A magl inhibitor
HK40100721A (en) A magl inhibitor
EA048915B1 (ru) Ингибитор magl
WO2026072966A2 (en) Pi3k degrader compounds and uses thereof
HK40078094A (en) Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
HK1262295A1 (en) 6,7-dihydro-5h-pyrazolo[5，1-b][1,3]oxazine-2-carboxamide compounds
OA18257A (en) Triazolopyrazinones as PDE 1 inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21811018

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022013766

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2023/0004649

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 3196119

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 140250140003000608

Country of ref document: IR

WWE Wipo information: entry into national phase

Ref document number: 2023524567

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202317029538

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202180073621.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: NC2023/0004649

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 16246

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 112022013766

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220711

ENP Entry into the national phase

Ref document number: 2021379081

Country of ref document: AU

Date of ref document: 20211112

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2023000733

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021811018

Country of ref document: EP

Effective date: 20230613

WWE Wipo information: entry into national phase

Ref document number: 523440403

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523440403

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 523440403

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 2021811018

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2025/0496

Country of ref document: RS

WWG Wipo information: grant in national office

Ref document number: P-2025/0496

Country of ref document: RS